// you're reading...

Congressos e Eventos

Nederland 2011 – 17th ISCT Annual Meeting– Rotterdam – Workshops

Os wokshops ocorreraram durante o ISCT Annual Meeting, e os textos disponibizados pela organização do congresso em inglês, estão aqui disponibilizados ou podem ser acessados no site: www.cellularatherapy2011.com

Workshop 1: Ex-Vivo Expansion (Joint Session with EBMT)
Thursday 5/19/2011
Time: 3:30pm – 5:00pm

Ex-vivo expansion represents the “Holy Grail” of stem cell biologists, and a hope to improve results of human stem cell transplantation, especially in situations where available grafts contain limited numbers of hematopoietic progenitors, such as in cord blood transplantation. Initial attempts mostly relied on the use of cytokine combinations, but have largely failed to produce clinically relevant results; the production of differentiated, mature and functional cells may however be feasible on a large scale and find applications within a near future in selected situations. Next generations of pre-clinical and clinical trials currently explore the possibility to manipulate other types of signals that more directly regulate stem cell behavior such as Notch. Recent results in murine models and in human trials suggest that such targets can be identified, and that their modulation can result in significant changes in hematopoietic stem cell activity associated with potential clinical benefits (enhanced hematopoietic recovery). The workshop will illustrate some of the recent developments in this field.
________________________________________
Workshop 2: Mesenchymal Stem/Stromal Cells and Tumors
Thursday 5/19/2011
Time: 3:30pm – 5:00pm

While large amount of data suggested the role of MSC as regenerative tools by differentiation, new intriguing insights are progressively indicating how these cells may be additionally acting in releasing relevant amounts of largely unknown bio-molecules to beused in different contexts of biomedicine.
Based on this background this workshop will address how wild type or gene modified MSC can be used as bio-molecules factories against cancer mimicking immune effectors within tumor stroma.
The speakers will here address the conflicting results on the role of MSC in cancer in parallel suggesting the role of MSC in inducing cancer death. The latest findings in the field will be presented opening novel roles of MSC in oncology and hematology.
________________________________________
Workshop 3: Antigen Specific T Cells
Thursday 5/19/2011
Time: 3:30pm – 5:00pm

Adoptive immunotherapy is emerging as a safe alternative to chemotherapeutic drugs for both viral infections and relapsed malignancies after hematopoietic stem cell transplantation (SCT). Despite showing efficacy against virus infection in numerous clinical trials, the lack of in vivo persistence of transferred T cells and their unproven effectiveness against various malignancies are challenges that have yet to be overcome. To date, most if not all adoptively transferred antigen-specific T cells have been derived from memory T cells. Therefore, virus-specific T cells –though shown to be effective for recipients of virus experienced donors- are unavailable for SCT recipients of cord blood or virus-seronegative donor grafts. Pre-clinical data on human antigen-specific T cells generated from naïve T cells has been scant and mostly limited to EBV or OKT3-stimulated T cells bearing exogenous TCRs. At this workshop session we will now present novel developments (both preclinical and clinical) demonstrating that antigen-specific T cells can be generated from human naïve T cells using GMP compliant technologies. In addition to viral infection, leukemic relapse remains a significant cause of SCT treatment failure. Hence, there is a need to develop additional strategies to enhance the graft versus leukemia (GVL) effect. New approaches to improve the GVL effect including vaccines to prime and boost leukemia specific T cells and adoptive transfer of ex vivo expanded leukemia specific cytotoxic T cells (CTL) will also be discussed at this session.
________________________________________
Workshop 4: How to improve in vivo vascularisation (Joint Session with TERMIS-EU)
Friday 5/20/2011
Time: 3:30pm – 5:00pm

When a tissue engineered construct is implanted in the body, survival of cells is a key point. Slow vascularisation of the graft is one of the major problems. There are different possible ways to improve vascularisation after implantation. In this symposium different approaches to obtain rapid vascularisation by engineering of new vessels in constructs will be discussed. We will make use of an automatic voting system and encourage discussion with challenging statements to have the audience actively involved.
Includes a structured discussion at the end (approximately 30 minutes)
________________________________________
Workshop 5: Dendritic Cells
Friday 5/20/2011
Time: 3:30pm – 5:00pm

Following Provenge’s FDA approval for DC vaccines on prostate cancer there is again an increasing scientific interest in clinical use of DC against cancer. Over the last 10 years many centers around the world have been working with DC vaccines. Most of these studies have been small non- randomized studies treating patients with resistant metastatic disease. Unfortunately, the success rate with DC vaccines has been highly variable with clinical responses between 0-20%. The reasons for these effects are multi-factorial and can not be explained only by the type of patients offered DC vaccines. This workshop will discuss which subtype of DC should be used, how to mature the DC in vitro, which antigen should be targeted in vivo, the route of administration of DCs, dose of DCs, frequency and duration of DC vaccination. Finally methods to break tolerance in vivo to improve clinical effects of DC vaccination will also be discussed.
________________________________________
Workshop 6: New Gene Transfer Technologies (Joint Session with ESGCT)
Saturday 5/21/2011
Time: 1:15pm – 2:45pm

Pivotal to the success of genetic engineering of therapeutic cells (e.g., immune effector cells; human stem/progenitor cells) is the availability of adequate gene transfer technologies, comprising both virus and non-virus based transfer methods. To date, retro-/lentiviral gene transfer is most wide spread in clinical applications, but bears drawback of ad random genomic integration with related safety concerns and gene silencing by host restriction factors. In this workshop we present promising new developments in both non-viral and viral gene therapy, including transposon-based methods (Dr. Izsvák), site specific gene editing using zinc finger nucleases (Dr. Rahman) as well as new developments in viral gene transfer (Dr. Rethwilm). In addition prospects of translation to clinical application will be discussed.
________________________________________
Workshop 7: Lung Regeneration
Saturday 5/21/2011
Time: 1:15pm – 2:45pm

Many lung diseases remain incurable or have poor therapeutic options. New approaches using both embryonic and adult stem cells provide new potential therapeutic options and are expected to be an area of rapid translational and clinical growth. Following an overview of the current state of the field, specific focus areas to be discussed will include immunomodulation of lung diseases by mesenchymal stromal cells (MSCs), clinical trials with MSCs and endothelial progenitor cells, cell therapy approaches for lung cancer, and bioengineering new lungs utilizing stem cells.

Milton Artur Ruiz

Sobre o Autor

Médico, Hematologista, Hemoterapeuta, Professor Colaborador da disciplina de Hematologia/Hemoterapia da Faculdade de Medicina da Universidade de S. Paulo, USP-SP, Coordenador do Grupo de Estudos de Terapia celular do IMC de S J do Rio Preto-SP, Chefe da Unidade de Transplante de Medula Óssea do Hospital Infante D. Henrique da Associação Portuguesa de Beneficencia de SJ do Rio Preto SP. , Editor da Revista Brasileira de Hematologia e Hemoterapia - Journal of Hematology and Hemotherapy ISSN 1516 8494 , Mestre em Hematologia – Escola Paulista de Medicina, Unifesp-SP, Doutor em Medicina Interna – Unicamp-SP, Livre docente em Hematologia- Famerp- SP.

Está no seu momento de descanso né? Entao clique aqui!